Noom Med
US$ 29.40
ada standards of care 2025 glp-1 receptor agonists recommendations in Diabetes Guidelines Must read for all doctors ▪️ Cardiovascular risk: Use RA or SGLT2 inhibitors for glycemic control & cardiovascular risk reduction. ▪️ Heart failure: ADA Standards of Care 2025
Description
Randomized controlled trials (RCTs) comparing insulin with established GLP-1 RAs, DPP-4is, or SGLT-2is were included
People who stop taking GLP-1 medications like Ozempic and Wegovy started to regain weight in a short amount of time, according to a new study.
Most Medicaid programs cover GLP-1s for Type 2 diabetes, but weight loss coverage varies
Here's what experts think.
Conventional wisdom says GLP-1 drugs must be taken indefinitely to maintain weight loss
A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro
